Professor He Xiaoming Elected President of the Society for Cryobiology
Release time:
2026-02-25
According to the latest announcement from the Society for Cryobiology, Professor He Xiaoming from the Institute of Biopharmaceutical and Health Engineering (iBHE) at Tsinghua University’s Shenzhen International Graduate School has been elected as the President-Elect of the society through a democratic vote by its global membership. In the past, the society's presidents were typically renowned scientists from European and American institutions. Professor He’s election makes him the first president from a Chinese university (and also from a non-European or non-American institution) to hold this position.
The Society for Cryobiology was founded in the United States in 1964 and is the earliest and most influential international academic organization in the field of cryobiology. The society is dedicated to advancing scientific research in the interdisciplinary field of cryobiology, enhancing scientific understanding in this area, and disseminating and applying this knowledge in medicine and environmental ecology for the benefit of humanity.
With the rapid development of cell-based medicine in recent years, cryobiology has become more important than ever. Cryobiological techniques are indispensable for ensuring the timely and convenient access to high-quality cells (including stem cells and immune cells), tissues, organs, and their derivatives, such as exosomes and organoids. Additionally, low-temperature and freezing processes have extensive applications in minimally invasive ablation, immunomodulation, medical aesthetics, pain management, and the production of specific biomaterials. Furthermore, cryobiology is closely linked to extreme environmental ecosystems.
Professor He Xiaoming is a tenured professor at Tsinghua University, a member of the European Academy of Sciences and Arts, a fellow of the American Institute for Medical and Biological Engineering (AIMBE), a fellow of the American Society of Mechanical Engineers (ASME), and a research scholar of the American Cancer Society. He earned his Ph.D. from the University of Minnesota in 2004 and conducted postdoctoral research at Harvard Medical School’s Massachusetts General Hospital. His research primarily focuses on developing micro- and nano-scale, micro-environmentally responsive biomaterials and medical devices for stem cell and immune engineering, as well as the preservation of biological systems—including exosomes, cells, tissues, and organs—at normal and low temperatures. He also works on the intelligent delivery of drugs, genes, and cells in vivo. During his time in the United States, his research was supported by major funding agencies, including the National Institutes of Health (NIH), the National Science Foundation (NSF), the American Cancer Society, and the Maryland Stem Cell Research Fund, with multiple significant projects, including eight NIH R01 grants. He has published over 150 articles in high-impact journals, including Nature Biomedical Engineering and Nature Nanotechnology. He served as the Vice Chair (2015–2018) and Chair (2018–2021) of the ASME Bioengineering Division’s BioTransport Committee and is currently the Editor-in-Chief of the ASME Journal of Medical Devices.
Previous article
Previous article
Latest developments
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
According to the latest announcement from the International Society of Cryobiology, Professor Xu Yi from the School of Health Science and Engineering at the University of Shanghai for Science and Technology, and a member of the Yinfeng Cryomedicine Expert Committee, has been elected as a Board Governor of the Society for a three-year term (2026–2028). The election was conducted through a democratic vote by all members worldwide, with three new Board Governors elected. Professor Xu Yi is the only scholar from Asia elected to the Society’s Board of Governors this time and the third elected scholar from mainland China in the Society’s 60-year history.
The significance of life extension lies not only in technological breakthroughs but also in the shared belief of every individual who believes in "a better future." With faith as their torch, these fellow travelers join hands, pooling their strength to stride forward together. We firmly believe that as this steadfast support converges into a powerful force, it will propel the Yinfeng Life Extension Plan to gain broader attention, inject continuous momentum into the development of cryobiomedicine, and illuminate the next chapter of human civilization.
Over the two days, the symposium was not only a collision of ideas but also seeds sown to advance social progress in life culture. The Shandong Yinfeng Life Science Public Welfare Foundation will continue to use technology as wings and culture as roots, collaborating with all sectors of society to enhance the quality of life for the Chinese people and build a human-centered life care system.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155507
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
